The filing pertains to an amendment of the stock plan, not a management change.

Unregistered Sales of Equity Securities. The disclosures in

Entry into a Material Definitive Agreement. On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”). The private placement closed on June 5, 2026. Pursuant to the purchase agreement, the Company offered and sold (i) pre-funded warrants to purchase up to 3,655…

Other Events. On June 2, 2026, the Company issued a press release announcing the pricing of the private placement, and on June 5, 2026, the Company issued a press release announcing the closing of the private placement. Copies of such press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference into this

Entry into a Material Definitive Agreement. On May 27, 2026, Bluejay Diagnostics, Inc. (the “Company”) entered into an agreement and statement of work (together, the “Agreement”) with Argonaut Manufacturing Services c/o Argonaut, Inc. (“Argonaut”) regarding the provision by Argonaut to the Company of certain manufacturing services to support the Company’s Symphony™ platform. The services include planning, engineering, sourcing, supply chain management, formulation, filling, finishing, quality…

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. On March 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement (the “Agreement”) pursuant to which the Company issued and sold to the purchasers named therein (the “Purchasers”) an aggregate of 62,500 shares (the “Securities”) of the Company’s common stock (“Common Stock”) at a price of $2.00 per share (such transaction, the “Private Placement”). The Private Placement closed on March 17, 2026 for aggregate…

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

of Form 8-K, the information regarding the Reverse Stock Split (as defined herein) contained in

Entry into a Material Definitive Agreement. On October 9, 2025, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement. The private placement closed on October 10, 2025. Pursuant to the purchase agreement, the Company offered and sold (i) an aggregate of 175,000 shares of the Company’s common stock (…

Unregistered Sales of Equity Securities. The disclosures in

Other Events. On October 9, 2025, the Company issued a press release announcing the pricing of the private placement, and on October 10, 2025, the Company issued a press release announcing the closing of the private placement. A copy of such press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference into this

Entry into a Material Definitive Agreement. On October 3, 2025, Bluejay Diagnostics, Inc. (the “Company”) entered into an agreement (the “Amendment”) to amend its Master Service Agreement and the Master Supply Agreement with Sanyoseiko Co., Ltd. (“Sanyoseiko”). The Amendment was entered into in connection with Bluejay expanding SanyoSeiko’s role in helping to commercialize Bluejay’s Symphony platform, a near-patient testing system designed to provide rapid and reliable results for key biomark…

Entry into a Material Definitive Agreement. On July 23, 2025, Bluejay Diagnostics, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its amended and restated license agreement (the “License Agreement”) and master supply agreement (the “Supply Agreement”) with Toray Industries, Inc. (“Toray”). The Amendment provides that the deadline under the License Agreement for the Company to establish an alternative manufacturing site for the Company’s Symphony cartridges has been extend…

Chief Technology Officer — Jason Cook: Dr. Jason Cook is leaving his role as Chief Technology Officer with the company.

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. On April 7, 2025, Bluejay Diagnostics, Inc. (the “Company”), entered into inducement letter agreements (the “Inducement Letter Agreements”) with certain existing holders (the “Holders”) of the Company’s existing Class C warrants, pursuant to which such Holders agreed to purchase an aggregate of 1,085,106 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), originally issued to the Holders on June 28, 2024 (the “Exi…

of Form 8-K, the information regarding the Reverse Stock Split (as defined herein) contained in

Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on March 4, 2024, on February 28, 2024, Bluejay Diagnostics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that because the closing bid price for the Company’s common stock, par value $0.0001 (the “Com…

Entry into a Material Definitive Agreement. On June 27, 2024, Bluejay Diagnostics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (the “Underwriter”), in connection with a firm commitment underwritten public offering (such transaction, the “Offering”) of 5,368,098 units (“Units”), each Unit consisting of one share of the Company’s common stock, par value $0.0001 per share, two Class C warrants each to purchase one share of c…

of Form 8-K, the information regarding the Reverse Stock Split (as defined herein) contained in

Unregistered Sales of Equity Securities. Reference is made to the disclosure set forth under

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Reference is made to the disclosure set forth under

Entry into a Material Definitive Agreement . On May 31, 2024, Bluejay Diagnostics, Inc. (the “Company”) entered into a Note Purchase Agreement with an accredited investor (the “NPA”), and a Securities Purchase Agreement with three accredited investors (the “SPA”). Under the terms of the NPA, an investor has agreed to provide the Company with a $1,000,000 cash subscription in exchange for the issuance of a senior secured note. The note will be repayable in an amount equal to $1,176,470, with t…